Kentucky Retirement Systems Has $2.34 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Kentucky Retirement Systems decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 11,901 shares of the medical research company’s stock after selling 164 shares during the quarter. Kentucky Retirement Systems’ holdings in IQVIA were worth $2,339,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of IQV. FMR LLC lifted its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA during the 3rd quarter valued at $147,683,000. JPMorgan Chase & Co. raised its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB raised its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV raised its position in shares of IQVIA by 68.5% during the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after acquiring an additional 250,458 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ? increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $190.94 on Friday. The stock has a 50-day moving average price of $199.57 and a two-hundred day moving average price of $216.49. The stock has a market cap of $33.62 billion, a PE ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on IQV. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Truist Financial reiterated a “buy” rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.